Discontinuation of antihyperglycemic therapy and clinical outcomes after acute myocardial infarction in older patients with diabetes

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 3, 2010, Pages 236-242

  Lipska, Kasia J ^a   Wang, Yongfei ^a   Kosiborod, Mikhail ^c   Masoudi, Frederick A ^d,e,f,g   Havranek, Edward P ^d,e   Krumholz, Harlan M ^a,b,g   Inzucchi, Silvio E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d DENVER HEALTH MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Division of General Internal Medicine   (United States)

^g Division of Cardiology Department of Medicine Denver Health Medical Center ^*  (United States)

Author keywords

Acute myocardial infarction; Antihyperglycemic medication; Diabetes mellitus; Hospital discharge

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SULFONYLUREA;

ACUTE HEART INFARCTION; AGED; ANTIHYPERGLYCEMIC THERAPY; ARTICLE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DRUG THERAPY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL; DIABETES MELLITUS, TYPE 2; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA; SURVIVAL; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MEDICARE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNITED STATES; WITHHOLDING TREATMENT;

EID: 77953419353     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.109.887620     Document Type: Article

References (21)

1. Stranders I, Diamant M, van Gelder R, Spruijt H, Twisk J, Heine R, Visser F. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004;164:982-988.
2. Kosiborod M, Rathore S, Inzucchi S, Masoudi F, Wang Y, Havranek E, Krumholz H. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078-3086.
3. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
4. Fath-Ordoubadi F, Beatt K. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-1156.
5. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenström A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-661.
6. Cheung N, Wong V, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765-770.
7. Díaz R, Goyal A, Mehta S, Afzal R, Xavier D, Pais P, Chrolavicius S, Zhu J, Kazmi K, Liu L, Budaj A, Zubaid M, Avezum A, Ruda M, Yusuf S. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA. 2007;298:2399-2405.
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
9. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen C, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan B, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
10. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P, Zieve F, Marks J, Davis S, Hayward R, Warren S, Goldman S, McCarren M, Vitek M, Henderson W, Huang G. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
11. Kenward K. The scope of the data available in the AMA's Physician Masterfile. Am J Public Health. 1996;86:1481-142.
12. American Hospital Association. The AHA Annual Survey Database: Fiscal Year 1998 and 2000 Documentation. Chicago, IL: American Hospital Association, Health Forum: 1999, 2001.
13. American Hospital Association. The AHA Annual Survey Database: Fiscal Year 2000 Documentation. Chicago, IL: Health Forum, American Hospital Association; 2001.
14. Fleming C, Fisher E, Chang C, Bubolz T, Malenka D. Studying outcomes and hospital utilization in the elderly: the advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care. 1992;30:377-391.
15. Krumholz H, Chen Y, Wang Y, Radford M. Aspirin and angiotensinconverting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction. Arch Intern Med. 2001;161:538-544.
16. Tansey M, Opie L. Relation between plasma free fatty acids and arrhythmias within the first twelve hours of acute myocardial infarction. Lancet. 1983;2:419-422.
17. Timmer J, Ottervanger J, de Boer M, Dambrink J, Hoorntje J, Gosselink A, Suryapranata H, Zijlstra F, van't Hof A. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005;45:999-1002.
18. Undas A, Wiek I, Stêpien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31:1590-1595.
19. Skyler J, Bergenstal R, Bonow R, Buse J, Deedwania P, Gale E, Howard
20. B, Kirkman M, Kosiborod M, Reaven P, Sherwin R. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351-357.
21. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, Spertus JA. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009;301:1556-1564.